Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Non-Current Liabilities (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Other Non-Current Liabilities data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 7.82% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, down 7.82%, while the annual FY2024 figure was $1.8 million, 7.24% down from the prior year.
  • Other Non-Current Liabilities reached $1.6 million in Q3 2025 per FBIO's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.3 million in Q2 2021 and bottomed at $1.6 million in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $2.0 million, with a median of $1.8 million recorded in 2022.
  • The widest YoY moves for Other Non-Current Liabilities: up 2657.97% in 2021, down 74.66% in 2021.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.0 million in 2021, then dropped by 9.15% to $1.8 million in 2022, then grew by 2.49% to $1.9 million in 2023, then decreased by 7.24% to $1.8 million in 2024, then fell by 7.97% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $1.6 million in Q3 2025, $1.7 million in Q2 2025, and $1.7 million in Q1 2025.